Mark Ordan: Was right in the mid-single-digit, Pito. Jim referenced and we’ve given similar comments in the second and third quarters that underlying trend was a little bit elevated from what we expected. Certainly not to the level of volatility you’ve seen elsewhere, but somewhat elevated, primarily related to the standup of new practices on behalf of our hospital partners and the €“ some of the difficulties in those expansions, in new recruiting and the like and the need for locums and others as we get staffing, right.
Jim Swift: Yes. It’s not unusual in that time period because of the holidays that we have €“ to have additional staffing opportunities or challenges of people taking time off. So, that’s probably baked in there as well.
Pito Chickering: Okay. So actually I want to ask differently, excluding sort of the higher cost labor kind of in general what was your core labor inflating in the fourth quarter?
Mark Ordan: We still had the same kind of directional comment there, Peter, right? Kind of in that mid single digit range. And within our outlook for 2023 versus the historical norm, we’re looking at somewhat elevated but not in a great fashion.
Pito Chickering: Okay. So, like if I were sort of
Marc Richards: By mid single-digit, like 4% to 5%. Yes.
Pito Chickering: Okay. So to Kevin’s question, you sort normalized pricing sort of 1% to 2% labor in place, inflating either low single digits or mid single digits. Just, what makes sort of this margin start increasing in the 2024 and beyond? Is it the pricing gets better than 1% to 2%? Is it the labor comes down to like 1% to 2% or is it the amount of gene leverage you can get off of, the business in order to help negate that that negative yield spread?
Marc Richards: There is a volume component in there as well, which carries operating leverage when it’s positive. So that’s just one thing to keep in mind in that equation. Jim, I don’t know if you want to add further?
Jim Swift: No.
Pito Chickering: All right, great. Thanks so much.
Operator: And next we can go to Brian Tanquilut with Jefferies. Please go ahead.
Brian Tanquilut: Hey, good morning guys. Hey Jim, just yes, try and put on your former BizDev that on. You know, as I think about, obviously there’s a lot of focus here on rev cycle near term, but once you got past that, how are you thinking about, where your focus is from a growth perspective and what do you think will be kind of like a good normalized growth rate to be thinking about maybe once we get to 2024?
Jim Swift: Yes, I think, what we’ve focused on in the last number of years and that we reported on this is really around the build out of our organic growth team, which really paid often dividends in terms of, sourcing opportunities with our hospital partners and also sourcing opportunities internal to us that we’re all around ambulatory services. What we’ve seen, going forward now is that, and I mentioned on the call, really these relationships with the hospitals where we have had, hospitals reach out to us and instead of it being a, one program they’re looking for, there’s a suite of programs that they want us to build out around women and children. So, we always talk about the fact that we’re not a staffing company, we’re a program building company and those programs we’re in women and children’s.
